KR102548066B1 - 섬유증의 소분자 억제제 - Google Patents

섬유증의 소분자 억제제 Download PDF

Info

Publication number
KR102548066B1
KR102548066B1 KR1020177018790A KR20177018790A KR102548066B1 KR 102548066 B1 KR102548066 B1 KR 102548066B1 KR 1020177018790 A KR1020177018790 A KR 1020177018790A KR 20177018790 A KR20177018790 A KR 20177018790A KR 102548066 B1 KR102548066 B1 KR 102548066B1
Authority
KR
South Korea
Prior art keywords
formula
compound
delete delete
alkyl
embodiments described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177018790A
Other languages
English (en)
Korean (ko)
Other versions
KR20170091154A (ko
Inventor
루크 라이르손
아르냅 케이 샤터지
마이클 볼롱
바이위엔 양
피터 지 슐츠
Original Assignee
더 스크립스 리서치 인스티튜트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 스크립스 리서치 인스티튜트 filed Critical 더 스크립스 리서치 인스티튜트
Publication of KR20170091154A publication Critical patent/KR20170091154A/ko
Application granted granted Critical
Publication of KR102548066B1 publication Critical patent/KR102548066B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N57/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
KR1020177018790A 2014-12-10 2015-12-09 섬유증의 소분자 억제제 Active KR102548066B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462090267P 2014-12-10 2014-12-10
US62/090,267 2014-12-10
US201562117846P 2015-02-18 2015-02-18
US62/117,846 2015-02-18
PCT/US2015/064814 WO2016094570A1 (en) 2014-12-10 2015-12-09 Small molecule inhibitors of fibrosis

Publications (2)

Publication Number Publication Date
KR20170091154A KR20170091154A (ko) 2017-08-08
KR102548066B1 true KR102548066B1 (ko) 2023-06-26

Family

ID=56108132

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177018790A Active KR102548066B1 (ko) 2014-12-10 2015-12-09 섬유증의 소분자 억제제

Country Status (9)

Country Link
US (1) US10336735B2 (enExample)
EP (1) EP3250036B1 (enExample)
JP (1) JP6706023B2 (enExample)
KR (1) KR102548066B1 (enExample)
CN (1) CN107404878B (enExample)
AU (1) AU2015360583B2 (enExample)
CA (1) CA2968874C (enExample)
ES (1) ES2879963T3 (enExample)
WO (1) WO2016094570A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11028078B2 (en) * 2011-09-07 2021-06-08 The Johns Hopkins University Itraconazole analogs and use thereof
US11571431B2 (en) 2013-12-04 2023-02-07 Galmed Research And Development Ltd Aramchol salts
EP3099679B1 (en) * 2014-02-01 2020-05-20 University of Connecticut Itraconazole analogues and methods of use thereof
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
US11197870B2 (en) 2016-11-10 2021-12-14 Galmed Research And Development Ltd Treatment for hepatic fibrosis
WO2019040363A1 (en) 2017-08-20 2019-02-28 University Of Connecticut Azole analogues and methods of use thereof
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US12435067B2 (en) 2019-08-09 2025-10-07 University Of Connecticut Truncated itraconazole analogues and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100092479A1 (en) 2008-08-18 2010-04-15 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
WO2014197738A1 (en) 2013-06-07 2014-12-11 The California Institute For Biomedical Research Small molecule inhibitors of fibrosis

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267179A (en) 1978-06-23 1981-05-12 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4619931A (en) 1983-02-28 1986-10-28 Janssen Pharmaceutica, N.V. [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles
US4791111A (en) 1985-12-23 1988-12-13 Janssen Pharmaceutica, N.V. [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles having anti-microbial properties
AU683515B2 (en) 1993-11-19 1997-11-13 Shell Internationale Research Maatschappij B.V. Polyketone polymer composition
US5521186A (en) 1994-10-27 1996-05-28 Janssen Pharmaceutica N.V. Apolipoprotein-β synthesis inhibitors
TW457240B (en) 1995-04-20 2001-10-01 Janssen Pharmaceutica Nv Novel triazolones as apolipoprotein-B synthesis inhibitors
EP0957101A1 (en) 1998-05-14 1999-11-17 Janssen Pharmaceutica N.V. Water soluble azoles as broad-spectrum antifungals
ATE253915T1 (de) 1999-06-30 2003-11-15 Merck & Co Inc Src-kinase hemmende verbindungen
US6414013B1 (en) 2000-06-19 2002-07-02 Pharmacia & Upjohn S.P.A. Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention
US7078526B2 (en) 2002-05-31 2006-07-18 Transform Pharmaceuticals, Inc. CIS-itraconazole crystalline forms and related processes, pharmaceutical compositions and methods
EP1655295A1 (en) * 2004-11-03 2006-05-10 Schering Aktiengesellschaft Anthranilamide pyridinureas as VEGF receptor kinase inhibitors
AU2007296740B2 (en) * 2006-09-11 2012-09-27 Curis, Inc. Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety
CN101896472A (zh) 2007-12-13 2010-11-24 锡耶纳生物技术股份公司 Hedgehog途径拮抗剂及其治疗应用
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US20110183948A1 (en) 2010-01-15 2011-07-28 Infinity Pharmaceuticals, Inc. Treatment of fibrotic conditions using hedgehog inhibitors
WO2012047762A2 (en) 2010-10-08 2012-04-12 Amplyx Pharmaceuticals, Inc. Antifungal agents
WO2013036866A1 (en) 2011-09-07 2013-03-14 The Johns Hopkins University Itraconazole analogs and use thereof
WO2013106485A2 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
JP6133431B2 (ja) 2012-11-24 2017-05-24 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用
MX366449B (es) 2013-06-07 2019-07-09 Rhizen Pharmaceuticals Sa Inhibidores de pi3 cinasa delta y gama selectivos duales.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100092479A1 (en) 2008-08-18 2010-04-15 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
WO2014197738A1 (en) 2013-06-07 2014-12-11 The California Institute For Biomedical Research Small molecule inhibitors of fibrosis

Also Published As

Publication number Publication date
US10336735B2 (en) 2019-07-02
AU2015360583A1 (en) 2017-06-22
EP3250036B1 (en) 2021-05-12
JP2017537937A (ja) 2017-12-21
ES2879963T3 (es) 2021-11-23
CA2968874C (en) 2024-06-18
CA2968874A1 (en) 2016-06-16
WO2016094570A1 (en) 2016-06-16
US20170362211A1 (en) 2017-12-21
CN107404878A (zh) 2017-11-28
EP3250036A1 (en) 2017-12-06
AU2015360583B2 (en) 2020-01-23
EP3250036A4 (en) 2018-06-27
KR20170091154A (ko) 2017-08-08
CN107404878B (zh) 2021-03-30
HK1249361A1 (zh) 2018-11-02
JP6706023B2 (ja) 2020-06-03

Similar Documents

Publication Publication Date Title
KR102240329B1 (ko) 섬유증의 소분자 억제제
KR102548066B1 (ko) 섬유증의 소분자 억제제
DE60126997T2 (de) Stickstoff-enthaltende aromatische ringverbindungen zur behandlung von tumorerkrankungen
JP4722851B2 (ja) キノリンカリウムチャネル阻害剤
US10155756B2 (en) Pyrazolo[1,5-A]pyridine compounds and use thereof
US20160038475A1 (en) Coumarin derivatives and methods of use in treating hyperproliferative diseases
DE112012004878T5 (de) Heterocyclische Dihydro-Fünfring-Ketonderivate als DHODH-Inhibitor und ihre Verwendung
JPWO2007043568A1 (ja) Ｓ１ｐ３受容体拮抗剤
HK1249361B (zh) 纤维化的小分子抑制剂

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170706

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201118

Comment text: Request for Examination of Application

PN2301 Change of applicant

Patent event date: 20210302

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220901

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230321

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230622

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230622

End annual number: 3

Start annual number: 1

PG1601 Publication of registration